Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Norway
  4. Oslo Bors
  5. SoftOx Solutions AS
  6. News
  7. Summary
    SOFTX   NO0010811961

SOFTOX SOLUTIONS AS

(SOFTX)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SoftOx Solutions AS: Strengthens the liquidity

10/14/2021 | 03:23am EST
The board of SoftOx Solutions AS has entered into a loan agreement with Almhaug
Bolig AS, where the main shareholder is one of the shareholders. Almhaug Bolig
AS will provide the company with a short-term loan of NOK 15 million.

"In the last year, the company has experienced some delays both in connection
with regulatory processes with the authorities and in the implementation of
certain clinical studies. To compensate for the liquidity burden caused by these
delays, the company's main shareholder has given the company a loan of NOK 15
million. Additional supply of liquidity may be considered if desired. The
company is grateful that the company's main shareholder shows his support for
the company I this situation. It is important for the company to have owners who
are dynamic and support the company financially in such situations", says CEO
Geir Almaas of SoftOx Solutions.

 "We work with several exciting processes. Among other things, we recently
received approval from the Danish Medicines Agency to start SIS (SoftOx
Inhalation solution) studies in humans. For us, this is a very exciting race,
which we have high expectations for", Almås continues.

The loan has a maturity of 12 months and is not interest-bearing. The loan will
in principle be repaid in cash, but until the maturity of the loan, Almhaug
Bolig AS will have the right to convert the loan into equity in the company by
issuing new shares at a price equal to the volume- weighted average share price
in the last five days before entering into the agreement, minus five percent,
NOK 38,551 per share. The board is of the opinion that the discount is
commercially justified as the loan is interest-free. If the company carries out
a share issue before the loan matures or is converted into shares, Almhaug Bolig
AS will have the right to convert the loan into shares at the same price per
share as the subscription price in such an issue.

New shares that may be issued in connection with the conversion right will be
approved by the company's board in accordance with the authorization given by
the annual general meeting on 13 April 2021. The board has assessed the loan
agreement and the right of conversion in relation to the rules on equal
treatment and is of the opinion that there is a valid reason for differential
treatment.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine M. Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange

All news about SOFTOX SOLUTIONS AS
01/17SOFTOX SOLUTIONS AS : Cancellation of subsequent offering
AQ
01/01SOFTOX SOLUTIONS AS : New share capital registered
AQ
2021SOFTOX SOLUTIONS AS : Minutes from extraordinary general meeting
AQ
2021SOFTOX SOLUTIONS AS : Mandatory notification for close associate
AQ
2021SOFTOX SOLUTIONS AS : New share capital registered
AQ
2021SOFTOX SOLUTIONS AS : Notice of extraordinary general meeting
AQ
2021SOFTOX : Presentation as of Desember 08.2021
PU
2021SOFTX : Ex. Right to receive subscription rights in potential repair offering
AQ
2021SOFTOX SOLUTIONS AS : Key information relating to potential repair offering
AQ
2021SOFTOX SOLUTIONS AS : Private placement successfully completed
AQ
More news
Financials
Sales 2020 9,84 M 1,12 M 1,12 M
Net income 2020 -37,4 M -4,25 M -4,25 M
Net cash 2020 34,8 M 3,95 M 3,95 M
P/E ratio 2020 -15,6x
Yield 2020 -
Capitalization 492 M 55,9 M 55,9 M
EV / Sales 2019 39,3x
EV / Sales 2020 58,6x
Nbr of Employees 23
Free-Float 57,6%
Chart SOFTOX SOLUTIONS AS
Duration : Period :
SoftOx Solutions AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SOFTOX SOLUTIONS AS
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Managers and Directors
Geir Hermod Almňs Chief Executive Officer
Kristine Mundal R°d Chief Financial Officer
Melvin Teigen Chairman
Glenn Gundersen Medical Director
Magnus Mustafa Fazli Head-Science & Research
Sector and Competitors
1st jan.Capi. (M$)
SOFTOX SOLUTIONS AS-15.00%56
GILEAD SCIENCES, INC.-3.00%88 346
REGENERON PHARMACEUTICALS-3.21%63 906
VERTEX PHARMACEUTICALS5.22%58 750
WUXI APPTEC CO., LTD.-0.66%54 178
BIONTECH SE-34.36%40 873